These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 35253502)

  • 1. Invasive Aspergillosis of the Spleen in the setting of Ibrutinib use.
    Asawa P; Chahine Z; Vusqa U; Samhouri Y; Fazal S
    J Oncol Pharm Pract; 2022 Oct; 28(7):1654-1658. PubMed ID: 35253502
    [No Abstract]   [Full Text] [Related]  

  • 2. Disseminated invasive aspergillosis in a patient treated with ibrutinib for chronic lymphocytic leukaemia.
    Booth E; Backx M; Joshi A; Nizami H; Elmusharaf N
    Br J Haematol; 2023 Nov; 203(4):499-500. PubMed ID: 37696766
    [No Abstract]   [Full Text] [Related]  

  • 3. Non-Aspergillus invasive mould infections in patients treated with ibrutinib.
    Anastasopoulou A; DiPippo AJ; Kontoyiannis DP
    Mycoses; 2020 Aug; 63(8):787-793. PubMed ID: 32458510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Aspergillus spondylodiscitis in a patient treated with ibrutinib].
    Petitdemange A; Martin A; Ruch Y; Chatron E; Karol A; Hansmann Y
    Med Mal Infect; 2020 May; 50(3):296-297. PubMed ID: 31722863
    [No Abstract]   [Full Text] [Related]  

  • 5. Cerebral aspergillosis in a patient on ibrutinib therapy.
    Creuzet E; Nourrisson C; Chaleteix C; Poirier P; Moniot M
    Br J Haematol; 2021 Jun; 193(6):1025. PubMed ID: 33748950
    [No Abstract]   [Full Text] [Related]  

  • 6. Incidence of Invasive Fungal Infections in Patients Initiating Ibrutinib and Other Small Molecule Kinase Inhibitors-United States, July 2016-June 2019.
    Gold JAW; Tolu SS; Chiller T; Benedict K; Jackson BR
    Clin Infect Dis; 2022 Aug; 75(2):334-337. PubMed ID: 34893821
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunomodulatory effect of ibrutinib: Reducing the barrier against fungal infections.
    Maffei R; Maccaferri M; Arletti L; Fiorcari S; Benatti S; Potenza L; Luppi M; Marasca R
    Blood Rev; 2020 Mar; 40():100635. PubMed ID: 31699465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infections in patients with lymphoproliferative diseases treated with targeted agents: SEIFEM multicentric retrospective study.
    Marchesini G; Nadali G; Facchinelli D; Candoni A; Cattaneo C; Laurenti L; Fanci R; Farina F; Lessi F; Visentin A; Marchesi F; Prezioso L; Spolzino A; Tisi MC; Trastulli F; Picardi M; Verga L; Dargenio M; Busca A; Pagano L;
    Br J Haematol; 2021 Apr; 193(2):316-324. PubMed ID: 33058237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence and associated risk factors for invasive fungal infections and other serious infections in patients on ibrutinib.
    Holowka T; Cheung H; Malinis M; Gan G; Deng Y; Perreault S; Isufi I; Azar MM
    J Infect Chemother; 2021 Dec; 27(12):1700-1705. PubMed ID: 34389223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ibrutinib induces multiple functional defects in the neutrophil response against
    Blez D; Blaize M; Soussain C; Boissonnas A; Meghraoui-Kheddar A; Menezes N; Portalier A; Combadière C; Leblond V; Ghez D; Fekkar A
    Haematologica; 2020; 105(2):478-489. PubMed ID: 31171644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ibrutinib related cerebral aspergillosis successfully treated with isavuconazole: a case report.
    Nyga R; Delette C; Mabille C; Bennis Y; Chouaki T; Boone M; Maizel J; Marolleau JP; Joseph C
    Leuk Lymphoma; 2020 Jul; 61(7):1760-1762. PubMed ID: 32090647
    [No Abstract]   [Full Text] [Related]  

  • 12. Cerebral Invasive Aspergillosis in a Case of Chronic Lymphocytic Leukemia with Bruton Tyrosine Kinase Inhibitor.
    Alkharabsheh O; Alsayed A; Morlote DM; Mehta A
    Curr Oncol; 2021 Feb; 28(1):837-841. PubMed ID: 33567487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ibrutinib-Induced Skin Rash.
    Kirar S; Gogia A; Gupta R; Mallick S
    Turk J Haematol; 2021 Feb; 38(1):81-83. PubMed ID: 33053966
    [No Abstract]   [Full Text] [Related]  

  • 14. Early morphea during treatment with ibrutinib in a patient with chronic lymphocytic leukemia.
    Ozbagcivan O; Akarsu S; Nazli EC; Lebe B; Fetil E
    Ann Hematol; 2021 Jan; 100(1):293-294. PubMed ID: 32221651
    [No Abstract]   [Full Text] [Related]  

  • 15. Severe Lymphocytosis in a Case of Diffuse Large B-Cell Lymphoma Treated by Ibrutinib.
    Paydaş S; Bayram E; Türker M; Özer T
    Turk J Haematol; 2021 Dec; 38(4):337-338. PubMed ID: 34380291
    [No Abstract]   [Full Text] [Related]  

  • 16. BTK Inhibition Impairs the Innate Response Against Fungal Infection in Patients With Chronic Lymphocytic Leukemia.
    Fiorcari S; Maffei R; Vallerini D; Scarfò L; Barozzi P; Maccaferri M; Potenza L; Ghia P; Luppi M; Marasca R
    Front Immunol; 2020; 11():2158. PubMed ID: 32983178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An oral drug for chronic lymphocytic leukemia.
    Koehler A
    JAAPA; 2020 Feb; 33(2):51-53. PubMed ID: 31990837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atypical Painful Purpuric Cutaneous Nodules With Ibrutinib.
    Marcaillou M; Stéphanie D; Marion B; Julien S; Christophe B
    Am J Dermatopathol; 2020 Dec; 42(12):1012-1014. PubMed ID: 32675466
    [No Abstract]   [Full Text] [Related]  

  • 19. Ibrutinib-related skin cancer: A pharmacovigilance study from the Food and Drug Administration Adverse Event Reporting System.
    Sun X; Ma Z; Guo Q; Zhao Z; Liu L
    Eur J Cancer; 2022 Jan; 160():277-278. PubMed ID: 34865944
    [No Abstract]   [Full Text] [Related]  

  • 20. Ibrutinib-Induced Cardiac Tamponade in Chronic Lymphocytic Leukemia.
    Kidoguchi K; Kubato Y; Nishimura Y; Kizuka-Sano H; Kimura S
    Turk J Haematol; 2021 Feb; 38(1):83-85. PubMed ID: 33161683
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.